Gallop Oncology
LYT-200
relapsed/refractory high-risk myelodysplastic syndrome
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on LYT-200 for relapsed/refractory high-risk myelodysplastic syndrome is in focus around Date TBD.
Primary source
· SEC 6-K
verified 12h ago
“Gallop has selected a recommended Phase 2 dose and intends to engage with the FDA to discuss the design of a subsequent trial in 2025.”